250 related articles for article (PubMed ID: 33765101)
41. Only Hyperuricemia with Crystalluria, but not Asymptomatic Hyperuricemia, Drives Progression of Chronic Kidney Disease.
Sellmayr M; Hernandez Petzsche MR; Ma Q; Krüger N; Liapis H; Brink A; Lenz B; Angelotti ML; Gnemmi V; Kuppe C; Kim H; Bindels EMJ; Tajti F; Saez-Rodriguez J; Lech M; Kramann R; Romagnani P; Anders HJ; Steiger S
J Am Soc Nephrol; 2020 Dec; 31(12):2773-2792. PubMed ID: 32938648
[TBL] [Abstract][Full Text] [Related]
42. Urate-lowering agents for asymptomatic hyperuricemia in stage 3 - 4 chronic kidney disease: Controversial role of kidney function.
Jeon HJ; Oh J; Shin DH
PLoS One; 2019; 14(6):e0218510. PubMed ID: 31206563
[TBL] [Abstract][Full Text] [Related]
43. Allopurinol and progression of CKD and cardiovascular events: long-term follow-up of a randomized clinical trial.
Goicoechea M; Garcia de Vinuesa S; Verdalles U; Verde E; Macias N; Santos A; Pérez de Jose A; Cedeño S; Linares T; Luño J
Am J Kidney Dis; 2015 Apr; 65(4):543-9. PubMed ID: 25595565
[TBL] [Abstract][Full Text] [Related]
44. Relationship between uric acid levels and risk of chronic kidney disease in a retrospective cohort of Brazilian workers.
Chini LSN; Assis LIS; Lugon JR
Braz J Med Biol Res; 2017 Aug; 50(9):e6048. PubMed ID: 28793050
[TBL] [Abstract][Full Text] [Related]
45. Renoprotective effects of febuxostat in hyperuricemic patients with chronic kidney disease: a parallel-group, randomized, controlled trial.
Tanaka K; Nakayama M; Kanno M; Kimura H; Watanabe K; Tani Y; Hayashi Y; Asahi K; Terawaki H; Watanabe T
Clin Exp Nephrol; 2015 Dec; 19(6):1044-53. PubMed ID: 25676011
[TBL] [Abstract][Full Text] [Related]
46. Comparison of febuxostat and allopurinol for hyperuricemia in cardiac surgery patients with chronic kidney disease (NU-FLASH trial for CKD).
Sezai A; Soma M; Nakata K; Osaka S; Ishii Y; Yaoita H; Hata H; Shiono M
J Cardiol; 2015 Oct; 66(4):298-303. PubMed ID: 25649025
[TBL] [Abstract][Full Text] [Related]
47. Prevalences of hyperuricemia and electrolyte abnormalities in patients with chronic kidney disease in Japan: A nationwide, cross-sectional cohort study using data from the Japan Chronic Kidney Disease Database (J-CKD-DB).
Sofue T; Nakagawa N; Kanda E; Nagasu H; Matsushita K; Nangaku M; Maruyama S; Wada T; Terada Y; Yamagata K; Narita I; Yanagita M; Sugiyama H; Shigematsu T; Ito T; Tamura K; Isaka Y; Okada H; Tsuruya K; Yokoyama H; Nakashima N; Kataoka H; Ohe K; Okada M; Kashihara N
PLoS One; 2020; 15(10):e0240402. PubMed ID: 33057377
[TBL] [Abstract][Full Text] [Related]
48. Hyperuricemia is an independent predictive factor for left ventricular diastolic dysfunction in patients with chronic kidney disease.
Gromadziński L; Januszko-Giergielewicz B; Pruszczyk P
Adv Clin Exp Med; 2015; 24(1):47-54. PubMed ID: 25923086
[TBL] [Abstract][Full Text] [Related]
49. Changeover Trial of Febuxostat and Topiroxostat for Hyperuricemia with Cardiovascular Disease: Sub-Analysis for Chronic Kidney Disease (TROFEO CKD Trial).
Sezai A; Unosawa S; Taoka M; Osaka S; Sekino H; Tanaka M
Ann Thorac Cardiovasc Surg; 2020 Aug; 26(4):202-208. PubMed ID: 31748427
[TBL] [Abstract][Full Text] [Related]
50. Risk factors associated with renal lithiasis during uricosuric treatment of hyperuricemia in patients with gout.
Perez-Ruiz F; Hernandez-Baldizon S; Herrero-Beites AM; Gonzalez-Gay MA
Arthritis Care Res (Hoboken); 2010 Sep; 62(9):1299-305. PubMed ID: 20506124
[TBL] [Abstract][Full Text] [Related]
51. Association of hyperuricemia with renal outcomes, cardiovascular disease, and mortality.
Liu WC; Hung CC; Chen SC; Yeh SM; Lin MY; Chiu YW; Kuo MC; Chang JM; Hwang SJ; Chen HC
Clin J Am Soc Nephrol; 2012 Apr; 7(4):541-8. PubMed ID: 22300737
[TBL] [Abstract][Full Text] [Related]
52. Hyperuricemia, Hypertension, and Chronic Kidney Disease: an Emerging Association.
Mallat SG; Al Kattar S; Tanios BY; Jurjus A
Curr Hypertens Rep; 2016 Oct; 18(10):74. PubMed ID: 27696189
[TBL] [Abstract][Full Text] [Related]
53. Comparison of long-term efficacy and renal safety of febuxostat and allopurinol in patients with chronic kidney diseases
.
Yang AY
Int J Clin Pharmacol Ther; 2020 Jan; 58(1):21-28. PubMed ID: 31657714
[TBL] [Abstract][Full Text] [Related]
54. Benefits of Allopurinol Treatment on Blood Pressure and Renal Function in Patients with Early Stage of Chronic Kidney Disease.
Satirapoj B; Wirajit O; Burata A; Supasyndh O; Ruangkanchanasetr P
J Med Assoc Thai; 2015 Dec; 98(12):1155-61. PubMed ID: 27004299
[TBL] [Abstract][Full Text] [Related]
55. Effect of treatment of hyperuricemia with allopurinol on blood pressure, creatinine clearence, and proteinuria in patients with normal renal functions.
Kanbay M; Ozkara A; Selcoki Y; Isik B; Turgut F; Bavbek N; Uz E; Akcay A; Yigitoglu R; Covic A
Int Urol Nephrol; 2007; 39(4):1227-33. PubMed ID: 17701281
[TBL] [Abstract][Full Text] [Related]
56. The Effect of Allopurinol on Renal Function.
Krishnamurthy A; Lazaro D; Stefanov DG; Blumenthal D; Gerber D; Patel S
J Clin Rheumatol; 2017 Jan; 23(1):1-5. PubMed ID: 28002149
[TBL] [Abstract][Full Text] [Related]
57. Uric Acid and Diabetic Nephropathy Risk.
Mauer M; Doria A
Contrib Nephrol; 2018; 192():103-109. PubMed ID: 29393137
[TBL] [Abstract][Full Text] [Related]
58. Elevated uric acid level as a significant predictor of chronic kidney disease: a cohort study with repeated measurements.
Chou YC; Kuan JC; Yang T; Chou WY; Hsieh PC; Bai CH; You SL; Chen CH; Wei CY; Sun CA
J Nephrol; 2015 Aug; 28(4):457-62. PubMed ID: 25410145
[TBL] [Abstract][Full Text] [Related]
59. Urate lowering therapy to improve renal outcomes in patients with chronic kidney disease: systematic review and meta-analysis.
Kanji T; Gandhi M; Clase CM; Yang R
BMC Nephrol; 2015 Apr; 16():58. PubMed ID: 25928556
[TBL] [Abstract][Full Text] [Related]
60. Uric acid and long-term outcomes in CKD.
Madero M; Sarnak MJ; Wang X; Greene T; Beck GJ; Kusek JW; Collins AJ; Levey AS; Menon V
Am J Kidney Dis; 2009 May; 53(5):796-803. PubMed ID: 19303683
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
